[2022] UKSC 14
On appeal from: [2020] EWCA Civ 617
JUDGMENT
Competition and Markets Authority (Respondent) v Flynn Pharma Ltd and another (Appellants)
Competition and Markets Authority (Respondent) v Pfizer Inc and another (Appellants)
before
Lord Hodge, Deputy President
Lord Sales
Lord Leggatt
Lord Stephens
Lady Rose
25 May 2022
Heard on 22 and 23 February 2022
Appellants (Flynn Pharma Ltd and Flynn Pharma (Holdings) Ltd)
Daniel Jowell QC
Tom Pascoe
(Instructed by Macfarlanes LLP)
Appellants (Pfizer Inc and Pfizer Ltd)
Mark Brealey QC
Tim Johnston
(Instructed by Clifford Chance LLP (London))
Respondent (Competition and Markets Authority)
Sir James Eadie QC
Rob Williams QC
David Bailey
Rupert Paines
(Instructed by Competition and Markets Authority)
1st Interveners (Association of the British Pharmaceutical Industry (ABPI) and British Generic Manufacturers Association (BGMA))
(written submissions only)
Daniel Piccinin
(Instructed by Bristows LLP (London))
2nd Intervener (Office of Communications (Ofcom))
(written submissions only)
Josh Holmes QC
Jessica Boyd
(Instructed by OFCOM)
3rd Intervener (Solicitors Regulation Authority Ltd (SRA))
(written submissions only)
Andrew Tabachnik QC
Ruth Keating
(Instructed by Solicitors Regulation Authority Ltd)
4th Intervener (Oakridge Farms Ltd)
(written submissions only)
Charles Streeten
(Instructed by Woodfines LLP (Milton Keynes))
LADY ROSE: (with whom Lord Hodge, Lord Sales, Lord Leggatt and Lord Stephens agree)
1.INTRODUCTION
The appellants in these proceedings were successful in an appeal which they brought before the Competition Appeal Tribunal (“the CAT”) under section 46 of the Competition Act 1998. In that appeal they challenged a decision adopted by the Respondent (“the CMA”) fining them for an infringement of competition law.
The CAT allowed the appellants’ appeal in part, set aside part of the CMA’s decision and remitted the decision to the CMA for reconsideration. On the appellants’ application for their costs of the appeal, the CAT made an order that the CMA pay the appellants a proportion of those costs. The Court of Appeal in the judgment now under appeal before this court set aside the CAT’s costs order and directed that there be no order as to costs. The Court of Appeal held that the CAT had erred in ordering the CMA to pay the appellants’ costs because it had disregarded a principle derived from a line of cases starting with Bradford Metropolitan District Council v Booth [2000] 164 JP 485. That principle was, the Court of Appeal held, that where, as here, a tribunal’s power to make an order about costs does not include an express general rule or default position, the starting point is that no order for costs should be made against a public body that has been unsuccessful in bringing or defending proceedings in the exercise of its statutory functions.
The appellants now appeal to this court arguing that the Court of Appeal was wrong to hold that the CAT’s discretion as to what costs order to make was constrained by any such principle. They argue that there is no such principle and that what is established by the case law is only that an important factor for a court or tribunal to take into account when considering costs is whether there is a risk that making adverse costs orders will have a “chilling effect” on the conduct of the public body concerned. By a risk of “chilling effect” they mean that the respondent public body might be so concerned about the risk of having to pay appellants’ costs in appeals against its decision that it is discouraged from making and standing by decisions which it takes reasonably in the performance of its statutory functions in the public interest. The appellants say further that the CAT is best placed to consider whether there is such a risk of “chilling effect” as regards the different public bodies that regularly appear as respondents before it, defending different kinds of regulatory or enforcement decisions. They argue that the CAT was right to conclude in its earlier case law, applied to their application for the costs of this appeal, that there is no reason to adopt a “no order as to costs” starting point in appeals like this one and every reason in general to award costs to a successful appellant in the absence of any particular circumstances pointing to a different result.
The CMA resists the appeal and supports the reasoning of the Court of Appeal.
2.BACKGROUND
(a)The CMA’s infringement decision
The CMA’s decision giving rise to these proceedings was published on 7 December 2016 entitled Unfair pricing in respect of the supply of phenytoin sodium capsules in the UK. Following a three year investigation, the CMA found that the appellants (“Flynn” and “Pfizer”) had abused their dominant position in the supply of the prescription epilepsy drug, phenytoin sodium, by charging excessive prices for the drug in capsule form. This was an infringement of section 18 of the Competition Act 1998 and of article 102 of the Treaty on the Functioning of the European Union. The CMA imposed a fine of £84.2m on Pfizer and £5.2m on Flynn. The decision included directions requiring Pfizer and Flynn to reduce their prices.
Both Flynn and Pfizer appealed against the infringement decision to the CAT. The hearing of the appeal lasted 13 days. The CAT (chaired by Peter Freeman CBE QC (Hon)) held that the CMA was right to find that the appellants held a dominant position in the relevant market but that the CMA had made errors in its assessment of whether the appellants had abused that dominant position. Part of the CMA’s decision was set aside and the CAT remitted the issue of abuse to the CMA for reconsideration in accordance with the CAT’s judgment: see the main substantive judgment of the CAT at [2018] CAT 11 and its ruling on remittal [2018] CAT 12.
The CMA appealed to the Court of Appeal against the substantive judgment of the CAT and there was a cross-appeal by Flynn. Both the appeal and the cross appeal were in large part dismissed by the Court of Appeal: [2020] EWCA Civ 339; [2020] Bus LR 803.
While the appeal from the CAT’s substantive judgment was pending before the Court of Appeal, the CAT dealt with the issue of the costs of the proceedings before it. The CAT delivered its ruling on costs on 29 March 2019: [2019] CAT 9 (“the CAT’s Costs Ruling”). The CAT had regard to what it described as “the relative successes and failures of the parties” and accepted that the appropriate overall approach would be to award the CMA its costs of defending Pfizer’s and Flynn’s claims in respect of market definition and dominance and to award Pfizer and Flynn a percentage of their costs in respect of the part of the appeal relating to abuse. The CAT decided “on a broad-brush basis” that approximately one third of the assessed costs should be deemed to relate to market definition/dominance, and two thirds to abuse. The CAT therefore considered that the CMA should pay Pfizer 58% of its allowable costs and Flynn 55% of its allowable costs.
In calculating what those allowable costs were, the CAT deducted some of the costs claimed by the appellants from the base sum to which the percentages would be applied. Pfizer’s and Flynn’s costs were limited to those incurred after the CMA’s decision so did not include costs incurred during the investigation stage. Pfizer’s costs of its expert economist were reduced by 40% on the basis that they were too high. The CAT noted that further substantial discounts might be made when the costs went to be assessed, given the high level of Pfizer’s costs.
The CMA appealed to the Court of Appeal against the CAT’s Costs Ruling and that appeal was successful. In a judgment handed down on 12 May 2020, the Court of Appeal (Lewison, Floyd and Arnold LJJ) allowed the appeal, set aside the CAT’s Costs Ruling and replaced it with no order for the costs of the proceedings before the CAT. That judgment (“the CA Judgment”) is at [2020] EWCA Civ 617 and is the judgment now before this court. Permission to appeal was granted by this court on 17 December 2020.
Permission was granted to a number of interveners to make written submissions to the court. The Association of the British Pharmaceutical Industry and the British Generic Manufacturers Association made a joint submission in support of the appellants. The Office of Communications (“Ofcom”) had been refused permission by the CAT to intervene in the costs applications ([2019] CAT 2) but was permitted to intervene in this appeal in support of the CMA. The Solicitors Regulation Authority Ltd (“SRA”) also intervened in support of the CMA. Those interveners need no introduction.
A company called Oakridge Farms Ltd (“Oakridge”) also intervened in support of the appellants. Oakridge is a farming enterprise which successfully appealed (under section 80 of the Environmental Protection Act 1990) against an abatement notice which alleged that the application of fertiliser to the land it farms was causing an odour nuisance. The magistrates’ court awarded Oakridge its costs of that appeal under section 64 of the Magistrates’ Courts Act 1980. The local authority appealed against the award of costs by way of case stated. That appeal is stayed, pending the decision of this court on this appeal.
(b)The CAT’s jurisdiction and its power to award costs
The CAT in its current form was established by section 12 of and Schedule 2 to the Enterprise Act 2002 (“the Enterprise Act”). It replaced the earlier appellate body the Competition Commission Appeal Tribunals which formed part of the Competition Commission with appeal panels convened as and when necessary. That in turn had replaced the Restrictive Practices Court which was established under the Restrictive Practices Court Act 1976 as the appellate body under the very different competition regime set up under the Restrictive Trade Practices Act 1976 and the Fair Trading Act 1973.
The Restrictive Practices Court Rules 1976 (SI 1976/1897) conferred a power on that court to order the payment of costs only in limited circumstances. Rule 58 provided that the court could make an order for costs against a party which had “been guilty of unreasonable delay, or of improper, vexatious, prolix or unnecessary steps in any proceedings … or of other unreasonable conduct (including, but without prejudice to the generality of the foregoing, a refusal to make any admission or agreement as to the conduct of the proceedings which he ought reasonably to have made)”.
When the Competition Commission Appeal Tribunals came into being, their rules made in 2000 (SI 2000/261) conferred the broad discretion that has been carried forward ever since. Rule 26(2) of those 2000 Rules provided:
“(2)The tribunal may at its discretion, at any stage of the proceedings make any order it thinks fit in relation to the payment of costs by one party to another in respect of the whole or part of the proceedings and, in determining how much the party is required to pay the tribunal may take account of the conduct of all parties in relation to the proceedings.”
The Enterprise Act established the CAT as entirely independent of the enforcement bodies whose decisions it reviews. A number of different jurisdictions were conferred on the CAT when it was first established and these have been added to over the years. There are now four main elements in the CAT’s case load.
First there are appeals from decisions taken by the competition enforcement authorities under the Competition Act 1998 (“the Competition Act”). The primary enforcement authority is now the CMA, which, broadly, took over these functions from the Office of Fair Trading (“the OFT”). The OFT itself took over the functions of the Director General of Fair Trading (“the DGFT”). These appeals include challenges like Flynn’s and Pfizer’s appeals against decisions which find that the addressee undertakings have committed infringements under section 2 of the Competition Act (anti-competitive agreements) known as the Chapter 1 prohibition or under section 18 of that Act (abuse of dominant position) known as the Chapter 2 prohibition. An appeal against an infringement decision under the Competition Act may challenge both liability and the penalty imposed or only the penalty. The sectoral regulators have concurrent jurisdiction to enforce the Chapter 1 and 2 prohibitions in their sector: see section 54(1) of the Competition Act and the Competition Act 1998 (Concurrency) Regulations 2014 (SI 2014/536).
Secondly there are appeals from decisions of the sectoral regulators, in particular Ofcom exercising functions under the Communications Act 2003 (“the Communications Act”). Most of the challenges to Ofcom decisions with which the CAT has been concerned arise from the exercise of Ofcom’s ex ante regulatory powers in the telecoms sector, that is to say its decisions about how telecoms providers should act in the future rather than investigating and punishing past conduct. One distinction that has been made in the cases is between Ofcom’s regulatory decisions and its dispute resolution decisions. Dispute resolution decisions are those taken under section 185 of the Communications Act. Section 185 provides, broadly, that a communications provider may refer a dispute it has with another communications provider to Ofcom, if the dispute concerns a matter specified in section 185. Such disputes can include disputes about the terms on which one provider gives access to its network to another provider, including how much it can charge to the provider seeking access. Regulatory decisions include the many different decisions that Ofcom makes under the Communications Act which implemented the EU Regulatory Framework for communications. This comprised five different EU directives requiring member states to confer powers and duties on a national regulatory authority (which is Ofcom in the UK) to set the terms and conditions on which the regulated companies supply services to customers and to each other. Section 192 of the Communications Act provides a route of appeal to the CAT from many of these decisions including both regulatory decisions and decisions resolving disputes under section 185.
Thirdly the CAT determines applications for the judicial review of decisions mostly made by the CMA in respect of merger and market investigations under the Enterprise Act. Under the merger control regime, there may be appeals by parties whose merger has been blocked but also by companies complaining that a merger has been cleared when, they assert, it should have been blocked. A market investigation can be carried out by the CMA, again broadly, where there are features of a market for goods or services in the UK which may be generating an adverse effect on competition. If the CMA finds that the market is not operating competitively it can impose remedies to mitigate those effects. Those remedies may take the form of orders requiring undertakings to cease specified conduct. The CAT can hear appeals from the imposition of such remedies. The CMA took over these functions which were previously performed by the OFT, the Competition Commission and the Secretary of State in 2014.
Finally, the CAT has a rapidly burgeoning first instance jurisdiction to hear claims for damages brought by a private party against another private party seeking compensation for losses arising from the defendant’s infringement of the competition rules. These include collective proceedings brought under sections 49A and 49B of the Competition Act claiming damages for competition law infringements.
The CAT has many other jurisdictions from regulators including other decisions of Ofcom in its role as the regulator of broadcasting, of the use of the radio spectrum and of postal services, some decisions of the Gas and Electricity Markets Authority, the Civil Aviation Authority and the Payment Systems Regulator. Its jurisdiction covers the whole of the United Kingdom.
The statutory power to make rules governing the CAT’s proceedings is conferred by section 15 of the Enterprise Act which reads (as amended):
“15(1) The Secretary of State may, after consulting the President [of the CAT] and such other persons as he considers appropriate, make rules (in this Part referred to as ‘Tribunal rules’) with respect to proceedings before the Tribunal including proceedings relating to the approval of a collective settlement under section 49A or 49B of the 1998 Act.
(2)Tribunal rules may make provision with respect to matters incidental to or consequential upon appeals provided for by or under any Act to the Court of Appeal or the Court of Session in relation to a decision of the Tribunal.
…
(4)The power to make Tribunal rules is exercisable by statutory instrument subject to annulment in pursuance of a resolution of either House of Parliament.
…”
Schedule 4 to the Enterprise Act makes further specific provision about Tribunal rules including, by paragraph 10, that Tribunal rules may make different provision for different kinds of proceedings.
The CAT’s original rules (the Competition Appeal Tribunal Rules 2003 (SI 2003/1372)) provided for costs and expenses as follows:
“55(1) For the purposes of these rules ‘costs’ means costs and expenses recoverable before the Supreme Court of England and Wales, the Court of Session or the Supreme Court of Northern Ireland.
(2)The Tribunal may at its discretion, subject to paragraph (3), at any stage of the proceedings make any order it thinks fit in relation to the payment of costs by one party to another in respect of the whole or part of the proceedings and in determining how much the party is required to pay, the Tribunal may take account of the conduct of all parties in relation to the proceedings.
(3)Any party against whom an order for costs is made shall, if the Tribunal so directs, pay to any other party a lump sum by way of costs, or all or such proportion of the costs as may be just. The Tribunal may assess the sum to be paid pursuant to any order under paragraph (1), (2) or (3) or may direct that it be assessed by the President, a chairman or the Registrar, or dealt with by the detailed assessment of a costs officer of the Supreme Court or a taxing officer of the Supreme Court of Northern Ireland or by the Auditor of the Court of Session.
(4)Unless the Tribunal otherwise directs, an order made pursuant to paragraphs (1) and (2) may be made in the decision, if the parties so consent, or immediately following delivery of the decision.
(5)The power to award costs pursuant to paragraphs (1) to (3) includes the power to direct any party to pay to the Tribunal such sum as may be appropriate in reimbursement of any costs incurred by the Tribunal in connection with the summoning or citation of witnesses or the instruction of experts on the Tribunal’s behalf. Any sum due as a result of such a direction may be recovered by the Tribunal as a civil debt due to the Tribunal.”
That was the rule which applied in the period during which the CAT’s case law about costs orders developed, as I describe below.
In 2014 there was a review chaired by Sir John Mummery of the CAT’s Rules prompted by the Government’s consultation on Streamlining Regulatory and Competition Appeals published in June 2013. The Expert Working Group formed by Sir John (of which I was a member) focused particularly on developments in the CAT’s jurisdiction in areas other than the ones with which this appeal is concerned, in particular the growth of the CAT’s case load in damages claims and the need to review the operation of the rules governing collective proceedings. Sir John’s report led to the promulgation of the Competition Appeal Tribunal Rules 2015 (SI 2015/1648) (“the 2015 Rules”).
Rule 4 of the 2015 Rules sets out the governing principles for the CAT’s procedure. They give a flavour of how the CAT runs its proceedings, with an emphasis on written cases and active management soon after the commencement of the proceedings and throughout. The CAT aims to identify the main issues early on, limiting the scope and length of oral proceedings and encouraging the parties to cooperate with each other and with the CAT: